Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Endocrinology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/JOE-15-0461PMID 26769912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

  2015cited by this paper
• Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes

  2015influential reference
• Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

  2015cited by this paper
• Brain reward‐system activation in response to anticipation and consumption of palatable food is altered by glucagon‐like peptide‐1 receptor activation in humans

  2015cited by this paper
• 24. Brain Reward-System Activation in Response to Anticipation and Consumption of Palatable Food Is Altered by GLP-1 Receptor Activation in Humans (384-OR)

  2015cited by this paper
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

  2014cited by this paper
• Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.

  2014cited by this paper
• GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

  2014cited by this paper
• Leptin therapy in type 2 diabetes

  2013cited by this paper
• Food related processes in the insular cortex

  2013cited by this paper
• A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon.

  2012cited by this paper
• Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies.

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• GSK1614343, a Novel Ghrelin Receptor Antagonist, Produces an Unexpected Increase of Food Intake and Body Weight in Rodents and Dogs

  2011cited by this paper
• Circulating glucose levels modulate neural control of desire for high-calorie foods in humans.

  2011cited by this paper
• Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

  2011cited by this paper
• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

  2011cited by this paper
• Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia.

  2010cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009influential reference
• Imaging of Brain Dopamine Pathways: Implications for Understanding Obesity

  2009cited by this paper
• Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009influential reference
• Modulation of taste sensitivity by GLP‐1 signaling

  2008cited by this paper
• Dissociating the Role of the Orbitofrontal Cortex and the Striatum in the Computation of Goal Values and Prediction Errors

  2008cited by this paper
• Widespread reward-system activation in obese women in response to pictures of high-calorie foods

  2008influential reference
• Relation Between Obesity and Blunted Striatal Response to Food Is Moderated by TaqIA A1 Allele

  2008cited by this paper
• Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study.

  2008cited by this paper
• Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals

  2007influential reference
• Neural mechanisms underlying obesity and drug addiction.

  2007cited by this paper
• Dr. Hawkins and Associates Reply

  2006cited by this paper
• Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

  2005cited by this paper
• How can drug addiction help us understand obesity?

  2005cited by this paper
• Images of desire: food-craving activation during fMRI

  2004cited by this paper
• The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: Depressed and Positive Affect in cancer patients and healthy reference subjects

  2004cited by this paper
• Exposure to appetitive food stimuli markedly activates the human brain

  2004cited by this paper
• Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

  2003cited by this paper
• Representation of pleasant and aversive taste in the human brain.

  2001cited by this paper
• A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

  2001cited by this paper
• Changes in brain activity related to eating chocolate: from pleasure to aversion.

  2001cited by this paper
• Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.

  2000cited by this paper
• Cortical activation induced by intraoral stimulation with water in humans.

  2000cited by this paper
• Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

  2000cited by this paper
• Central nervous system control of food intake

  2000cited by this paper
• Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

  2000cited by this paper
• Taste memory induces brain activation as revealed by functional MRI.

  1999cited by this paper
• Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system

  1999cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.

  1996cited by this paper
• The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome

  1996cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996cited by this paper
• Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

  1994cited by this paper
• Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men.

  1992cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

  1987cited by this paper
• Scoring the eating disorder inventory.

  1986influential reference
• Effect of intracerebroventricularly infused glucagon on feeding behavior.

  1984cited by this paper
• Rapid development of tolerance to the behavioural actions of cholecystokinin

  1983cited by this paper

• Potential role of glucagon like peptide 1 in taste receptors

  2026cites this paper
• Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

  2026cites this paper
• Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

  2025cites this paper
• Intestinal short-chain fatty acid turnover is not associated with resting state functional connectivity in mesolimbic dopaminergic network in healthy adults

  2025cites this paper
• Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

  2025cites this paper
• Domain‐Specific and Domain‐General Functional Brain Alterations in Type 2 Diabetes Mellitus: A Task‐Based and Functional Connectivity Meta‐Analysis

  2025cites this paper
• The anxiolytic effects of glucagon-like peptide 1 functional agonists in diabetes: A systematic review and meta-analysis

  2025cites this paper
• Effect of GLP-1 receptor agonists on body composition.

  2025cites this paper
• The gut–brain axis in appetite, satiety, food intake, and eating behavior: Insights from animal models and human studies

  2024cites this paper
• Symptom perception in adults with chronic physical disease: A systematic review of insular impairments.

  2024cites this paper
• Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review.

  2024cites this paper
• Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice

  2024cites this paper
• Intestinal acetate and butyrate availability is associated with glucose metabolism in healthy individuals

  2023cites this paper
• Neuroimaging Investigations of Obesity: a Review of the Treatment of Sex from 2010

  2023cites this paper
• Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes

  2022cites this paper
• Assessment of Eating Disorders and Eating Behavior to Improve Treatment Outcomes in Women with Polycystic Ovary Syndrome

  2022cites this paper
• Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

  2022cites this paper
• Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis

  2022cites this paper
• Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study

  2022cites this paper
• Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial

  2022cites this paper
• Update on the management of diabetes in long-term care facilities

  2022cites this paper
• Factors associated with successful weight loss after liraglutide treatment for obesity

  2022cites this paper
• Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial

  2022cites this paper
• Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.

  2022cites this paper
• Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis

  2021cites this paper
• Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol

  2021cites this paper
• The Gut–Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation

  2021cites this paper
• Chicken C/EBPζ gene: Expression profiles, association analysis, and identification of functional variants for abdominal fat.

  2021cites this paper
• Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial

  2021cites this paper
• Exendin(9‐39)NH2: Recommendations for clinical use based on a systematic literature review

  2021cites this paper
• Incretins in the Therapy of Diabetic Kidney Disease

  2021cites this paper
• Gut-brain mechanisms underlying changes in disordered eating behaviour after bariatric surgery: a review

  2021cites this paper
• High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination

  2021cites this paper
• Computational approaches to predicting treatment response to obesity using neuroimaging

  2021cites this paper
• Anagliptin, a dipeptidyl peptidase‐4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation

  2020cites this paper
• Motivation: key to a healthy lifestyle in people with diabetes? Current and emerging knowledge and applications

  2020cites this paper
• Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches

  2020cites this paper
• Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress

  2020cites this paper
• Neural responses to food cues in middle to older aged adults: a scoping review of fMRI studies.

  2020cites this paper
• Glucagon-like peptide-1, a matter of taste?

  2020cites this paper
• Reduced neural satiety responses in women affected by obesity.

  2020cites this paper
• Changes in the expression levels of CB1 and GLP‐1R mRNAs and microRNAs 33a and 122 in the liver of type 2 diabetic rats treated with ghrelin

  2019cites this paper
• Children Obesity, Glucose Tolerance, Ghrelin, and Prader Willi Syndrome

  2019cites this paper
• Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?

  2019cites this paper
• The Role of Glucagon-Like Peptide-1 in Energy Homeostasis

  2019cites this paper
• Brain functional imaging in obese and diabetic patients

  2019cites this paper
• Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.

  2019cites this paper
• Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies

  2019cites this paper
• Of mice and men: incretin actions in the central nervous system.

  2019cites this paper
• Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People

  2019cites this paper
• Influences of Dietary Added Sugar Consumption on Striatal Food-Cue Reactivity and Postprandial GLP-1 Response

  2018cites this paper
• Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin

  2018cites this paper
• Brain, Environment, Hormone-Based Appetite, Ingestive Behavior, and Body Weight

  2018cites this paper
• Brain reward responses to food stimuli among female monozygotic twins discordant for BMI

  2017cites this paper
• Just a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones.

  2017cites this paper
• The safety of albiglutide for the treatment of type 2 diabetes

  2017cites this paper
• Identification of a potential functional single nucleotide polymorphism for fatness and growth traits in the 3'-untranslated region of the PCSK1 gene in chickens.

  2017cites this paper
• The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

  2017cites this paper
• Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.

  2017cites this paper
• Human brain responses to gastrointestinal nutrients and gut hormones.

  2016cites this paper